PepGen Inc
PEPG1.310USD
-0.010-0.76%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
42.86MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PepGen Inc Unternehmen
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Unternehmensinformationen
BörsenkürzelPEPG
Name des UnternehmensPepGen Inc
IPO-datumMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Anzahl der mitarbeiter81
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse245 Main St, 2nd Floor
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon17034568000
Websitehttps://pepgen.com
BörsenkürzelPEPG
IPO-datumMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 23
Aktualisiert: Fri, May 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
32.67%
Oxford Science Enterprises PLC
14.53%
Point72 Asset Management, L.P.
8.18%
Suvretta Capital Management, LLC
5.08%
Viking Global Investors LP
4.53%
Other
35.01%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
32.67%
Oxford Science Enterprises PLC
14.53%
Point72 Asset Management, L.P.
8.18%
Suvretta Capital Management, LLC
5.08%
Viking Global Investors LP
4.53%
Other
35.01%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
47.26%
Hedge Fund
27.63%
Investment Advisor/Hedge Fund
8.80%
Investment Advisor
8.03%
Sovereign Wealth Fund
3.80%
Research Firm
0.46%
Individual Investor
0.27%
Pension Fund
0.06%
Bank and Trust
0.05%
Other
3.65%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
165
31.53M
96.35%
-5.19M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
2023Q1
108
18.62M
78.36%
-609.71K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
10.69M
32.67%
--
--
Mar 31, 2025
Oxford Science Enterprises PLC
4.76M
14.53%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.68M
8.18%
+804.74K
+43.01%
Mar 31, 2025
Suvretta Capital Management, LLC
1.66M
5.08%
--
--
Mar 31, 2025
Viking Global Investors LP
1.48M
4.53%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.35M
4.13%
+550.00K
+68.75%
Mar 31, 2025
Qatar Investment Authority
1.24M
3.8%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
1.19M
3.64%
+2.10K
+0.18%
Mar 31, 2025
Millennium Management LLC
1.03M
3.16%
+876.38K
+559.50%
Mar 31, 2025
The Vanguard Group, Inc.
899.73K
2.75%
-12.94K
-1.42%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
